Geneuro SA (GNRO)

Paris
Currency in EUR
0.14
+0.01(+7.63%)
Closed
GNRO Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
0.130.18
52 wk Range
0.042.35
Key Statistics
Edit
Prev. Close
0.13
Open
0.13
Day's Range
0.13-0.18
52 wk Range
0.04-2.35
Volume
666.53K
Average Volume (3m)
443.53K
1-Year Change
-87.27%
Book Value / Share
-0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GNRO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Geneuro Company Profile

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program. In addition, the company has a collaborative development agreement with The National Institute of Neurological Disorders and Strokes for the development of an antibody program to block the activity of pHERV-K Env; and FondaMental Foundation for the development of diagnostic and therapeutic options for patients with Post-COVID neuropsychiatric syndromes, as well as research collaboration agreement with Northwestern University to confirm evidence of the expression of human endogenous retrovirus W envelope protein (W-ENV or W-ENV) in long-haul COVID patients; and US National Institute of Health for developing new approaches against pHERV-K (K-ENV) protein as a target in the treatment of amyotrophic lateral sclerosis. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Compare GNRO to Peers and Sector

Metrics to compare
GNRO
Peers
Sector
Relationship
P/E Ratio
−0.2x−5.9x−0.6x
PEG Ratio
0.010.000.00
Price/Book
−0.2x3.1x2.6x
Price / LTM Sales
-5.9x3.1x
Upside (Analyst Target)
25.0%105.6%47.1%
Fair Value Upside
Unlock4.3%8.1%Unlock

Earnings

Latest Release
Nov 27, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

0.2990
ALAGO
-9.16%
31.10
ALSTI
0.00%
0.31
ALNMR
-8.82%
0.59
ALMUN
+9.26%
0.09
ALTHO
-25.21%

FAQ

What Is the Geneuro (GNRO) Stock Price Today?

The Geneuro stock price today is 0.14

What Stock Exchange Does Geneuro Trade On?

Geneuro is listed and trades on the Paris stock exchange.

What Is the Stock Symbol for Geneuro?

The stock symbol for Geneuro is "GNRO."

What Is the Geneuro Market Cap?

As of today, Geneuro market cap is 4.05M.

What is Geneuro Earnings Per Share?

The Geneuro EPS is -0.594.

From a Technical Analysis Perspective, Is GNRO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.